In one study, a significant increase in TARC was observed in the sera of ALS patients [69], and recently, in a clinical trial, TARC expression was monitored for its possible role in controlling cytopathic microglial activation during ALS progression [70]. Here, CCL17 is linked to amyotrophic lateral sclerosis.